Anonymous User
Login / Registration

Gastroenterologie
a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2015; 69(5): 455–471. doi:10.14735/amgh2015455.

Standard diagnostic and therapeutic approaches to chronic hepatitis C virus infection

Petr Urbánek Orcid.org  1, Petr Husa2, Jan Šperl Orcid.org  3, Soňa Fraňková Orcid.org  3, Stanislav Plíšek Orcid.org  4, Luděk Rožnovský5, Petr Kümpel Orcid.org  6

+ Affiliation

Literature

1. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60 (2): 392–420. doi: 10.1016/j.jhep.2013.11.003.
2. Jensen DM, O’Leary JG, Pockros PJ et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: realworld experience in a diverse, longitudinal observational cohort. Hepatology 2014; 60: 219A.
3. Dieterich D, Bacon BR, Flamm SL et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. Hepatology 2014; 60: 220A.
4. Lawitz E, Sulkowski MS, Ghalib R et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384 (9956): 1756–1765. doi: 10.1016/S0140-6736 (14) 61036-9.
5. Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370 (3): 211–221. doi: 10.1056/NEJMoa1306218.
6. Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370 (20): 1889–1898. doi: 10.1056/NEJMoa1402454.
7. Bourlire M, Bronowicki JP, de Ledinghen V et al. Ledipasvir/sofosbuvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed protease-inhibitor based triple therapy. Hepatology 2014; 60: 1271A.
8. Feld JJ, Kowdley KV, Coakley E et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370 (17): 1594–1603. doi: 10.1056/NEJMoa1315722.
9. Ferenci P, Bernstein D, Lalezari J et al. ABT-450/rombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370 (21): 1983–1992. doi: 10.1056/NEJMoa1402338.
10. Wyles DL, Sulkowski MS, Eron JJ et al. TURQUOISE-I: 94% SVR12 in HCV/HIV-1 coinfected patients treated with ABT-450/r/ombitasvir, dasabuvir and ribavirin. Hepatology 2014; 60: 1136A.
11. Zeuzem S, Jacobson IM, Baykal T et al. Retreatment of HCV with ABT-450/ r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370 (17): 1604–1614. doi: 10.1056/NEJMoa1401561.
12. Andreone P, Colombo MG, Enejosa JV et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147 (2): 359–365. doi: 10.1053/j.gastro.2014.04.045.
13. Poordad F, Hezode C, Trinh R et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370 (21): 1973–1982. doi: 10.1056/NEJMoa1402869.
14. Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368 (20): 1867–1877. doi: 10.1056/NEJMoa1214854.
15. Zeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370 (21): 1993–2001. doi: 10.1056/NEJMoa1316145.
16. Esteban R, Nyberg L, Lalezari J et al. Successful retreatment with sofosbuvir-containing regimens for HCV genotype 2 or 3 infected patients who failed prior sofosbuvir plus ribavirin therapy. J Hepatol 2014; 60 (1): S4–S5. doi: 10.1016/S0168-8278 (14) 60010-6.
17. Lawitz E, Poordad F, Brainard DM et al. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study. Hepatology 2013; 58: 1380A.
18. Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368 (20): 1878–1887. doi: 10.1056/NEJMoa1214853.
19. Nelson DR, Cooper JN, Lalezari JP et al. Alloral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study. Hepatology 2015; 61 (4): 1127–1135. doi: 10.1002/hep.27726.
20. Moreno C, Hezode C, Marcellin P et al. Efficacy and safety of simeprevir with PegIFN/ribavirin in naive or experienced patients infected with chronic HCV genotype 4. J Hepatol 2015; 62 (5): 1047–1055. doi: 10.1016/j.jhep.2014.12.031.
21. Kapoor R, Kohli A, Sidharthan S et al. All-oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial. Hepatology 2014; 60: 321A.
22. Pol S, Reddy KR, Baykal T et al. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results. Hepatology 2014; 60: 1129A.
23. Castera L, Sebastiani G, Le Bail B et al. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010; 52 (2): 191–198. doi: 10.1016/j.jhep.2009.11.008.
24. Castéra L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128 (2): 343–350.
25. Lawitz E, Forns X, Zeuzem S et al. Simeprevir (TMC435) with peginterferon/ /ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferonbased therapy: results from PROMISE, a Phase III trial. Gastroenterology 2013; 144 (5): 151. doi: 10.1016/S0016-5085 (13) 60542-9.
26. Gane EJ, Stedman CA, Hyland RH et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368 (1): 34–44. doi: 10.1056/NEJMoa1208953.
27. Sulkowski M, Rodriguez-Torres M, Lalezari J et al. All-Oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). Hepatology 2013; 58 (Suppl 1): 313A–314A.
28. Fontana RJ, Hughes EA, Bifano M et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 13 (6): 1601–1605. doi: 10.1111/ajt.12209.
29. Zeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir plus ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Hepatology 2013; 58 (Suppl 1): 733A.
30. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47 (RR-19): 1–39.

Print pdf

Credited self-teaching test

Start test

Most Read (last 6 month)

  1. Colorectal cancer screening in the Czech Republic
  2. Pancreatic cancer surveillance in high-risk individuals Position statement of professional societies
  3. Trends in premature mortality from digestive system cancers in Slovakia in the years 2011–2020: 8 diagnoses over 10 years
  4. Results from the evaluation of colorectal cancer screening in the Czech Republic
  5. Mixed adenoneuroendocrine carcinoma of the stomach – a case report
  6. Subcutaneous infliximab in the treatment of refractory Crohn‘s disease patients – a pilot study of drug immunogenicity
  7. Urolithiasis in patients with inflammatory bowel disease – possibilities of prevention and metabolic influence
  8. Subcutaneous infliximab – treatments and new possibilities after clinical practice